Thomas Zander

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Top Venues

JCO precision oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of cancer research and clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Yelena Y Janjigian, Jaffer A Ajani, Markus Möhler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Elena Elimova, Michalis V Karamouzis, Ricardo Bruges, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Ruben Kowalyszyn, Roberto A Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Yelena Y Janjigian, Jaffer A Ajani, Markus Möhler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Elena Elimova, Michalis V Karamouzis, Ricardo Bruges, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Ruben Kowalyszyn, Roberto A Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Yelena Y Janjigian, Jaffer A Ajani, Markus Möhler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Elena Elimova, Michalis V Karamouzis, Ricardo Bruges, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Ruben Kowalyszyn, Roberto A Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Yelena Y Janjigian, Jaffer A Ajani, Markus Möhler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Elena Elimova, Michalis V Karamouzis, Ricardo Bruges, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Ruben Kowalyszyn, Roberto A Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Yelena Y Janjigian, Jaffer A Ajani, Markus Möhler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M Cleary, Elena Elimova, Michalis V Karamouzis, Ricardo Bruges, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Ruben Kowalyszyn, Roberto A Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Volker Arndt, Daniela Doege, Stefan Fröhling, Peter Albers, Hana Algül, Ralf Christian Bargou, Carsten Bokemeyer, Martin Bornhäuser, Christian H Brandts, Peter Brossart, Sara Yvonne Brucker, Tim Henrik Brümmendorf, Hartmut Döhner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia M Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. Journal of cancer research and clinical oncology (2022)
Sascha Hoppe, Lydia Meder, Florian Gebauer, Roland T Ullrich, Thomas Zander, Axel Maximilian Hillmer, Reinhard Buttner, Patrick Sven Plum, Julian Puppe, Wolfram Malter, Alexander Quaas
Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Cancers 14 (19) (2022)